81.25MMarket Cap-1.90P/E (TTM)
2.8600High2.6750Low140.76KVolume2.7300Open2.7000Pre Close392.96KTurnover0.70%Turnover RatioLossP/E (Static)28.86MShares5.740052wk High1.00P/B56.93MFloat Cap2.220052wk Low--Dividend TTM20.22MShs Float1889.9991Historical High--Div YieldTTM6.85%Amplitude1.6200Historical Low2.7910Avg Price1Lot Size
VistaGen Therapeutics Stock Forum
Breakthrough Pain Treatment Patent: Vistagen's Non-Opioid AV-101 Shows Promise Against Gabapentin
Vistagen Receives U.S. Patent for Av-101 to Treat Neuropathic Pain
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Wednesday, 5th February at 8:30 am
Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatmen...
Vistagen Announces Positive Results From Exploratory Phase 2a Study of Ph284 in Cancer Cachexia
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
Tuesday, 14th January at 8:30 am
PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patients
PH284 is the fifth pherine product candidate in Vistagen's neuroscience pipeline with a positive efficacy signal
Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircu...
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
Friday, 10th January at 8:30 am
All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway
Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in ...
500k shares buy usd3!!
No comment yet